Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

May 23 2018

• By Peter Chang

Listen to this article

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.

Render illustration of Clinical Trial title on medical documents

Regeneron Pharmaceuticals Inc. and Sanofi released positive data for Dupixent (dupilumab) in two studies at the American Thoracic Society (ATS) International Conference in San Diego May 18-23, but despite some differences in profiles, the data don't eliminate questions about which biologic physicians will prefer to treat severe uncontrolled asthma. The data were simultaneously published in the New England Journal of Medicine.

Experts at ATS called for pragmatic comparison trials to help inform the issue down the line. The LIBERTY ASTHMA VENTURE...

More from Respiratory

Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Mar 10 2025
• By Andrew McConaghie
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown
Aug 14 2024
• By Alaric DeArment
Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.